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Abstract
Chagas disease, caused by the protozoan Trypanosoma cruzi, is a life-long and debilitating illness 
of major significance throughout Latin America, and an emergent threat to global public health. 
Being a neglected disease, the vast majority of Chagasic patients have limited access to proper 
diagnosis and treatment, and there is only a marginal investment into R&D for drug and vaccine 
development. In this context, identification of novel biomarkers able to transcend the current limits 
of diagnostic methods surfaces as a main priority in Chagas disease applied research. The 
expectation is that these novel biomarkers will provide reliable, reproducible and accurate results 
irrespective of the genetic background, infecting parasite strain, stage of disease, and clinical-
associated features of Chagasic populations. In addition, they should be able to address other still 
unmet diagnostic needs, including early detection of congenital T. cruzi transmission, rapid 
assessment of treatment efficiency or failure, indication/prediction of disease progression and 
direct parasite typification in clinical samples. The lack of access of poor and neglected 
populations to essential diagnostics also stress the necessity of developing new methods 
operational in Point-of-Care (PoC) settings. In summary, emergent diagnostic tests integrating 
these novel and tailored tools should provide a significant impact on the effectiveness of current 
intervention schemes and on the clinical management of Chagasic patients. In this chapter, we 
discuss the present knowledge and possible future steps in Chagas disease diagnostic applications, 
as well as the opportunity provided by recent advances in high-throughput methods for biomarker 
discovery.
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INTRODUCTION
Chagas disease or American Trypanosomiasis, caused by the parasitic protozoan 
Trypanosoma cruzi (Kinetoplastida, Trypanosomatidae), is a life-long, neglected tropical 
disease, and leading cause of cardiomyopathy in endemic areas (Rassi, Rassi and Marin-
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Neto, 2010). With 8 to 10 million people already infected and up to 120 million individuals 
at risk of infection, Chagas disease constitutes the most important parasitic disease in Latin 
America and one of the most common globally (Stanaway and Roth, 2015). Its exact burden 
is however difficult to assess due to several factors including the widespread geographic 
distribution of T. cruzi vector-borne transmission, the decades-long lag between infection 
and appearance of symptoms, certain pitfalls of current diagnostic methods, biased 
prevalence data, and incomplete recognition of Chagas disease-attributable symptoms 
(Stanaway and Roth, 2015). The most recent estimates indicate that Chagas disease is 
responsible for ~550,000 disability adjusted life years (DALY), a measure that captures both 
premature mortality (~12,000 deaths per year) and non-fatal health losses (Stanaway and 
Roth, 2015). Despite this enormous toll, only two trypanocydal drugs, benznidazole and 
nifurtimox are currently available for chemotherapy. Both are nitroheterocyclic, oral 
compounds that require prolonged administration, may display severe adverse effects, 
cannot be used to treat pregnant women due to their uncertain teratogenic risks and, most 
importantly, show high efficacy solely if administered at the onset of infection (Carlier and 
Truyens, 2015; Rassi, Rassi and Marin-Neto, 2010; Viotti et al., 2006). The prospects for the 
development of an effective vaccine for prophylactic and/or therapeutic purposes, on the 
other hand are still clouded by substantial scientific and socioeconomic challenges 
(Beaumier et al., 2016; Bustamante and Tarleton, 2015).
T. cruzi transmission primarily occurs when humans are exposed to the contaminated feces 
of infected, hematophagous triatomine vectors. Large-scale intervention schemes launched 
in different regions of Latin America in the 1990’s have successfully shrunk the geographic 
limits and prevalence of vector-borne parasite transmission, and led to an overall ~40% 
reduction of disease prevalence (Schofield, Jannin and Salvatella, 2006). However, different 
ecological and demographic issues converged in the last decades to shift the epidemiological 
landscape for this disease. For instance, recent outbreaks of acute cases in certain regions 
from Brazil and Venezuela were not strictly vector-borne but rather due to accidental 
ingestion of T. cruzi-tainted food and fluids (Alarcon de Noya et al., 2010; Segovia et al., 
2013). This 'food-borne' transmission mode likely constitutes an ancient epidemiological 
trait, very important to the zoonotic spreading of the parasite (Gurtler and Cardinal, 2015), 
and appears to be associated with increased virulence and a higher case-fatality rate in 
humans (Alarcon de Noya et al., 2010; Segovia et al., 2013). In addition, migratory trends of 
infected populations from rural areas to urban centers and/or to non-endemic regions along 
with changes in the eco-geographical distribution of vector populations have led to the 
gradual urbanization and globalization of Chagas disease, which is now recognized as an 
emerging worldwide threat to public health (Eisenstein, 2016). Indeed, the risk of acquiring 
Chagas disease through infected blood transfusion and organ transplantation is becoming a 
major problem even in areas of non-endemicity, such as the United States, Australia and 
Europe (Requena-Mendez et al., 2015; Schmunis and Yadon, 2010). Moreover, the 
congenital route of infection, which constitutes the main transmission mode of T. cruzi in 
non-endemic areas is now estimated to be responsible for 22% of new annual infections in 
endemic countries with active programs for home vector infestations control (Carlier and 
Truyens, 2015).
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In this scenario, a strong and global partnership aimed to coordinate actions to control 
parasite transmission is urgently needed. In particular, we need to redouble our efforts to 
control home vector infestation, to screen blood supplies and to identify and subsequently 
treat T. cruzi-infected people who are still in the early stages of the disease to avoid 
sequelae, morbidity and economic losses. As a major step towards these goals, we ought to 
develop novel biomarkers able to overcome the limitations of current diagnostic 
applications. In this chapter, we critically appraise what has so far been achieved in this area. 
We also discuss possible ways to proceed in order to address major and still unmet 
diagnostic demands, and the opportunity provided by recent advances in high-throughput 
methods (i.e. peptide synthesis technology, genomics, and proteomics) in Chagas disease 
biomarker discovery.
TRYPANOSOMA CRUZI, AN 'ALL-WHEEL DRIVE' PARASITE
T. cruzi is a promiscuous parasite that traverses a complex life-cycle involving extracellular 
proliferation and differentiation inside hematophagous insect vectors from different genera, 
and intracellular proliferation and differentiation in a variety of vertebrate hosts (De Souza, 
2002). Host switching, immune pressure as well as constant transition from intracellular to 
extracellular niches (and vice versa) pose significant adaptation challenges, and are 
concomitantly accompanied by extensive remodeling of different aspects of T. cruzi such as 
intracellular transport, primary metabolism, gene expression profiling and overall cellular 
architecture (De Souza, 2002). This striking plasticity can be also readily recognized in the 
diverse genetic, phenotypic and epidemiological features displayed by different strains and 
field isolates comprised within the T. cruzi taxon (Zingales et al., 2012). In this first section, 
we outline some aspects that underlie the biological flexibility of this 'all-wheel drive' 
parasite, and that may be relevant in terms of biomarker discovery for Chagas disease 
diagnostic purposes.
EPIDEMIOLOGICAL FEATURES
Potential T. cruzi vectors present a broad geographic distribution (from central Argentina 
and Chile to southern USA) and include more than 140 species of 'kissing bugs' from the 
subfamily Triatominae (Hemiptera, Reduviidae). Of these, only a few (i.e. Triatoma 
infestans, T. dimidiata, T. brasiliensis, Rhodnius prolixus and Pastrongylus megistus) have 
adapted to live in domiciliary setting and to blood-feed on humans and/or domestic animals 
and thus define the 'domestic/peridomestic' cycle of Chagas disease (Gurtler and Cardinal, 
2015; Zingales et al., 2012). The 'sylvatic' cycle of T. cruzi, on the other hand, is actually an 
array of poorly understood cycles with different eco-epidemiological properties, each one 
involving multiple sylvatic and/or synanthropic triatomine species, which in turn feed on a 
variable range of animals. The latter include a variety of rodents, primates, c arnivores, bats, 
marsupials (i.e. opossums) and xenarthrans (i.e. armadillos, sloths, anteaters) (Figure 1) 
(Fernandes et al., 1999; Noireau, Diosque and Jansen, 2009; Zingales et al., 2012). In 
general terms, and although not yet fully established, all mammals are considered 
susceptible whereas birds and reptiles are considered refractory to T. cruzi. From an 
epidemiological standpoint, these non-human hosts may play key roles as parasite reservoirs 
and/or as determinant factors affecting T. cruzi transmission dynamics in endemic areas 
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(Gurtler and Cardinal, 2015; Noireau, Diosque and Jansen, 2009). Importantly, they may 
also work as complex selective systems leading to the emergence of novel parasite traits 
(Noireau, Diosque and Jansen, 2009).
Interestingly, distinct though partially overlapping sets of strains circulate in the ‘domestic/
peridomestic’ and the ‘sylvatic’ cycles of T. cruzi (Gurtler and Cardinal, 2015; Noireau, 
Diosque and Jansen, 2009; Zingales et al., 2012). In the last decades, environmental 
alterations and demographic issues converged in favoring the intermingling of the two 
cycles. This translates into an steady increase of emergent transmission patterns involving 
'exotic' T. cruzi genotypes, with the possible occurrence of atypical disease 
physiopathologies (Coura et al., 2002; Zingales et al., 2012).
GENETIC AND PHENOTYPIC VARIABILITY
As revealed for several pathogenic protozoa and fungi, T. cruzi displays a basically clonal 
reproduction mode, with occasional events of genetic exchange leading to the emergence of 
hybrid genotypes (Messenger and Miles, 2015). These features led to a complex population 
structure, made up of multiple 'clonal' strains showing remarkable genetic diversity 
(Tibayrenc and Ayala, 2015). Inter-strain variations may be grasped at the nucleotide level 
(Ackermann et al., 2012) but also structurally, in terms of dosage/diversification of antigenic 
gene families (Campo et al., 2004; Cerqueira et al., 2008; Llewellyn et al., 2015; Urban et 
al., 2011), DNA content and overall genome architecture (Lewis et al., 2009a; Minning et 
al., 2011; Reis-Cunha et al., 2015; Souza et al., 2011). Importantly, biochemical and genetic 
typing schemes developed throughout the last decades converged in the delineation of six 
major T. cruzi evolutionary lineages or discrete typing units (DTUs) termed TcI to TcVI, 
with multiple strains and even cryptic sub-lineages within each DTU (Tibayrenc and Ayala, 
2015; Zingales et al., 2012). A potential seventh lineage, termed TcBat, has been recently 
identified in South and Central American bats (Marcili et al., 2009; Pinto et al., 2012). So 
far, and although all six (or seven, including TcBat) T. cruzi DTUs are capable of infecting 
humans, certain DTUs such as TcI, TcII, TcV and TcVI are most frequently isolated from 
clinical samples (Ramirez et al., 2014; Zingales et al., 2012). The reasons for this skewed 
distribution are unclear, although current evidence suggest that parasite strains detected in 
patients reflect the principal DTUs circulating among 'domestic/peridomestic' cycles in that 
geographical area (Messenger, Miles and Bern, 2015).
T. cruzi genotypic heterogeneity could also be grasped at the phenotypic level when different 
biological parameters are studied. These include, for instance, the rate of epimastigote 
proliferation in the vector midgut (Castro et al., 2012; de Lana et al., 1998; Vieira et al., 
2016); and the extent of epimastigote differentiation into metacyclic trypomastigotes, the 
developmental form that bring the infection into vertebrates (Figure 1) (da Silveira Pinto et 
al., 2000; de Lana et al., 1998). The molecular basis for these differences are not yet 
understood but they might be related to the dissimilar resistance capacity of parasite strains 
to antimicrobial peptides or hemolytic factors and/or to their differential interaction with 
receptor(s) inside the crop of triatomines (Castro et al., 2012; Gonzalez et al., 2013; Vieira et 
al., 2016). Importantly, these biological traits define both T. cruzi infectivity toward insect 
vectors and its potential transmissibility to vertebrate hosts (Figure 1). These, together with 
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differential eco-geographical distribution and certain preference of triatomids for their 
blood-source are in turn major determinants of Chagas disease epidemiology (Gurtler and 
Cardinal, 2015; Noireau, Diosque and Jansen, 2009; Zingales et al., 2012).
Parasite genotypic heterogeneity also seems to modulate key aspects of its interaction with 
vertebrate hosts, including humans. For instance, the capacity of metacyclic trypomastigotes 
to resist the harsh conditions of the gastric milieu and to invade gastric epithelium following 
oral infection is largely dependent on the strain-specific glycoprotein composition of their 
surface coat (Camandaroba, Pinheiro Lima and Andrade, 2002; Hoft et al., 1996; Maeda et 
al., 2016). In the same line, inter-strain genetic variations underpin a variety of biological 
traits involved in parasite infectivity and long-term persistence such as antigenic profile, 
subversion of the immune system, host cell invasion capacity, intracellular growth rate and 
survival of amastigotes, and sensitivity to anti-Chagasic drugs (Figure 1) (Magalhaes et al., 
2015; Martin et al., 2006; Moraes et al., 2014; Mortara et al., 2008; Nagajyothi et al., 2012; 
Ruiz et al., 1998; Toledo et al., 2003). In contrast, no clear association between a particular 
T. cruzi genotype and an eventual tropism for congenital transmission could be yet 
established. Even though distinct strains may display subtle differences in their ability to 
invade trophoblasts or chorionic villi explants in vitro (Castillo et al., 2013), genetic 
profiling experiments have conclusively shown that i) the same set of strains circulate in the 
bloodstream of transmitting and non-transmitting mothers, and ii) nearly identical T. cruzi 
genetic signatures are recovered from infected infants born to Chagasic mothers coursing 
concurrent, multi-strain infections (Figure 1) (Burgos et al., 2007; del Puerto et al., 2010; 
Virreira et al., 2006a). Overall, the actual consensus is that maternal parasite load and human 
polymorphisms constitute the main risk factors for T. cruzi congenital transmission (Bua et 
al., 2012; Fabbro et al., 2014; Juiz et al., 2016; Kaplinski et al., 2015; Rendell et al., 2015).
Interestingly, certain (though not all) epidemiological studies have shown a partial 
correlation between the prevalence of particular clinical manifestations of Chagas disease 
and the genotype of the infecting strain (Andrade, Brodskyn and Andrade, 1983; D'Avila et 
al., 2009; Luquetti et al., 1986; Macedo and Pena, 1998; Virreira et al., 2006b; Zafra et al., 
2011; Zingales et al., 2012). This may be attributed in part to the genetic aspects and 
immune competence of local human populations (Ayo et al., 2013; Deng et al., 2013; Frade 
et al., 2013; Luz et al., 2016; Nogueira et al., 2012) and/or to parasite genetic 
heterogeneities. The latter hypothesis finds support in animal studies (that do not strictly 
recapitulate Chagas disease-associated physiopathologies), which revealed inter-strain 
variations in complex phenotypes such as parasitemia, virulence, tissue tropism/distribution 
and pathogenicity (Figure 1) (Andrade et al., 1999; Andrade, 1990; Camandaroba, Pinheiro 
Lima and Andrade, 2002; de Souza et al., 1996; Laurent et al., 1997; Monteiro et al., 2013; 
Revollo et al., 1998; Roellig et al., 2010). However, generalized conclusions are difficult to 
derive, particularly because these epidemiological studies might have been skewed by a 
number of intrinsic shortcomings. Briefly, i) they often lacked detailed genetic/clinical 
information on the studied populations; ii) the infecting genotype has been in some cases 
inferred based on the prevailing parasite genotypes circulating in the area and not typed 
directly from patients; iii) patients might have been co-infected with other co-endemic 
pathogens that impact on the clinical presentation of Chagas disease (Salvador et al., 2016); 
iv) patients might have been infected with multiple parasite strains, which is usually the case 
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in endemic areas (Perez, Lymbery and Thompson, 2014); and v) these studies might have 
been biased due to parasite typing pitfalls (i.e. samples were collected only from peripheral 
blood, which may not be representative of the situation within affected organs (Manoel-
Caetano Fda et al., 2008; Vago et al., 2000)) and/or associations between local parasites and 
disease, making it difficult to determine whether the absence of a specific strain/DTU in 
patients with a given disease phenotype is due to parasite factors or to lack of patient 
exposure to this DTU.
Overall, and although this issue may have major implications for Chagas disease diagnosis 
and treatment, the existence of particular associations between T. cruzi genotype and 
susceptibility to different clinical presentations on Chagasic patients remains to be addressed 
(Messenger, Miles and Bern, 2015).
DIAGNOSTIC APPLICATIONS FOR CHAGAS D ISEASE: PRESENT 
KNOWLEDGE
PARASITOLOGICAL AND CLINICAL METHODS
Upon T. cruzi infection, patients undergo the acute phase of Chagas disease, which extends 
for 40–60 days. Symptoms, if indeed occur, are usually very mild and atypical, thus often 
misleading its clinical recognition (Rassi, Rassi and Marin-Neto, 2010). In rare cases of 
vector-borne transmission, a skin nodule (called 'chagoma') or painless prolonged eyelid 
edema (called the 'Romanha's sign') may indicate the site of parasite inoculation. Due to the 
patent parasitemia verified at this initial phase, conventional microscopy (i.e. visualization of 
circulating trypomastigotes in peripheral blood films or buffy coat smears) remains the gold 
standard for diagnosis, both in acute cases and in newborns that were infected congenitally 
(Freilij and Altcheh, 1995; Gomes, Lorena and Luquetti, 2009). Either direct tests or 
concentration tests (i.e. microhematocrit or Strout test) are routinely used for this purpose. 
These techniques, however present certain limitations in terms of sensitivity (~80–90%), and 
commonly require highly trained personnel (Table 1) (Freilij and Altcheh, 1995; Gomes, 
Lorena and Luquetti, 2009).
Following the initial, acute phase, if untreated, patients enter the indeterminate form of the 
chronic phase that may last for several years or persist indefinitely (Rassi, Rassi and Marin-
Neto, 2010). This phase is characterized by the absence of relevant clinical symptoms and 
very low and intermittent or null parasitemia. During this phase, parasite replication is 
maintained in check by the elicitation of a strong and parasite-specific B- and T-cell-
mediated immunity (Tarleton, 2015), being the latter the most important in terms of 
controlling the infection. However, elaborate pathogen immune evasion systems (Albareda 
et al., 2009; Giraldo et al., 2013; Padilla, Simpson and Tarleton, 2009; Paiva et al., 2012; 
Vasconcelos et al., 2012) and their ability to quickly invade host cells (Mortara et al., 2008; 
Nagajyothi et al., 2012) turn this immune response only partially effective, and most patients 
maintain a sub-patent infection for life. T. cruzi reactivation in immunocompromised 
Chagasic patients provides solid support to this hypothesis (Tarleton, 2015). Direct T. cruzi 
detection during the chronic phase requires biological amplification methods, such as 
hemoculture and xenodiagnosis (Brener, 1962), which are also difficult, expensive, time-
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consuming and require special laboratory bio-security conditions. In the case of 
xenodiagnosis, in addition, it is not applicable to certain patient populations. Most 
importantly, these methods yield positive results in only a proportion of serologically 
positive patients, thus limiting their usefulness in diagnosis and/or in monitoring drug 
efficacy (Table 1).
Up to 20 years after the infection, ~35% of patients develop pathological signs characteristic 
of Chagas disease such as cardiomyopathy, peripheral nervous system damage or 
dysfunction of the digestive tract often leading to megaesophagus and/or megacolon (Rassi, 
Rassi and Marin-Neto, 2010). These pathological changes can be revealed by 
electrocardiogram clinical diagnosis, X-rays and ultrasound. The nature and relative 
contribution of the multiple factors involved in this quite broad pathogenic range has been 
the subject of intense debate (Bonney and Engman, 2015; Machado et al., 2012; Teixeira et 
al., 2011). The current consensus states that a failure to down-regulate the inflammatory 
response, which is maintained by parasite persistence in tissues, appears to play a 
predominant role. Other contributory factors include sex, age and genotypic features of the 
patient, route of infection, sustained vector exposure, auto-immune responses and the 
existence of co-infections (Ayo et al., 2013; Bonney and Engman, 2015; Deng et al., 2013; 
Frade et al., 2013; Luz et al., 2016; Machado et al., 2012; Nogueira et al., 2012; Tarleton, 
2015; Teixeira et al., 2011). As mentioned, a possible role of parasite genotype on Chagas 
disease progression/outcome has been proposed, though further research supported by novel 
and robust epidemiologic and diagnostic tools, and appropriate animal models are needed to 
address this issue.
SEROLOGICAL METHODS
Considering that patients seroconvert early upon infection, detection of anti-T. cruzi 
antibodies remains the most effective method for demonstrating direct exposure to the 
parasite (Gomes, Lorena and Luquetti, 2009). At present, the most widely used serologic 
methods are Indirect Hemagglutination Assay (IHA), Indirect Immunofluorescence Assay 
(IFA), and Enzyme-Linked ImmunoSorbent Assay (ELISA) (Table 1). First generation 
ELISA tests were originally developed using total parasite homogenates or, later on, using 
biochemically purified, parasite antigenic fractions. Among the latter, TESA 
(Trypomastigote Excreted/Secreted Antigens) and F2/3 (highly O-glycosylated 
trypomastigote mucins obtained by sequential solvent partitions) demonstrated the highest 
diagnostic potential (Table 1) (Almeida et al., 1997; Umezawa, Shikanai-Yasuda and Stolf, 
1996). In addition to ELISA, multiple techniques including dot blot and Western blot were 
developed for the evaluation of these reagents.
In the late 1980's, the advent of recombinant DNA technology allowed the generation of 
parasite DNA or cDNA expression libraries, which were then coupled to high-throughput 
screenings using serum samples from Chagasic patients or experimentally infected animals. 
These approaches provided the first glimpses into the genomic make up of this parasite and, 
most importantly, led to a 'golden era' of T. cruzi antigen discovery. Indeed, by using these 
methods several of the immunodominant T. cruzi antigens that are still in use were identified 
and characterized (Burns et al., 1992; Cotrim et al., 1990; Hoft et al., 1989; Houghton et al., 
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1999; Ibanez, Affranchino and Frasch, 1987; Ibanez et al., 1988; Lafaille et al., 1989; Levin 
et al., 1989). For a complete list of these antigens (henceforth the 'parental repertoire'), see 
Table 1. The fact that many of them emerged from independent screenings carried out in 
different laboratories further supported their diagnostic potential but, unfortunately also led 
to a confusing nomenclature that still persist (Table 1) (reviewed in (da Silveira, Umezawa 
and Luquetti, 2001; Frasch et al., 1991)). Some of the antigens included in the T. cruzi 
'parental repertoire' were extensively validated, in certain cases by way of multicenter trials 
(Caballero et al., 2007; Reithinger et al., 2010), and set the stage for the development of 
second-generation Chagas disease diagnostic methods. A variety of antigen expression 
procedures (i.e. using full-length or partially deleted recombinant, fusion proteins or 
synthetic peptides functionalized in different ways) and antigen display strategies (i.e. using 
mono- or multi-epitopic molecules) were evaluated before them being incorporated either 
individually or in defined mixtures into in-house and/or commercial kits (Godsel et al., 
1995; Hernandez et al., 2010; Houghton et al., 2000; Krieger et al., 1992; Longhi et al., 
2012; Oelemann et al., 1999; Pastini et al., 1994). Some of these tests have shown very good 
performances, and were thus extensively used in basic research and/or as confirmatory tests 
in clinical practice up to this day.
The major advantage of recombinant antigens-based tests is that they minimize the extent of 
specificity problems. As previously shown, sera from individuals with other co-endemic 
infections such as leishmaniasis and/or afflicted of certain autoimmune disorders cross-react 
with crude preparations of T. cruzi antigens (Araujo, 1986; Gomes, Lorena and Luquetti, 
2009; Schnaidman et al., 1986). On the down side, they present lower sensitivity than whole 
parasite-based techniques. In addition, it should be said that the proven success of this 
'parental repertoire', along with a shift in R&D priorities converged in curbing the 
enthusiasm for subsequent large-scale antigen-discovery efforts for Chagas disease. Indeed, 
most of the additional antigens/biomarkers with moderate-to-excellent diagnostic 
performance that emerged in the last decades were identified either as by-products of basic 
hypothesis-driven research (Buchovsky et al., 2001; Di Noia et al., 2002; Martinez et al., 
1991; Saborio et al., 1990) or using low-to-medium throughput antigen expression/synthesis 
approaches (see below). Most importantly, just a few of these novel antigens have been 
incorporated into the already existing diagnostic application platforms.
New generation tests displaying potentially improved accuracy such as the 
Chemoluminescent Microparticle ImmunoAssay (CMIA) and its improved version, 
Architect Chagas (both from Abbott Laboratories, Wiesbaden, Germany) (Abras et al., 2016; 
Praast et al., 2011), or the Multi-cruzi test (InfYnity Biomarkers, Lyon, France) (Granjon et 
al., 2016) have been recently developed. Confirming the above mentioned trend, both use a 
large panel of T. cruzi antigens belonging to the 'parental repertoire' -those discovered in the 
80's-, which in the case of the Multi-cruzi test is supplemented with TSSA (Trypomastigote 
Small Surface Antigen (Di Noia et al., 2002)). Despite the virtual lack of antigen innovation, 
these tests incorporate a large degree of automation and highly sensitive detection systems 
(Abras et al., 2016) or major technical improvements, such as a multiplexed printing method 
inside ELISA microplates (Granjon et al., 2016).
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Overall, currently available serodiagnostic tests are simple, affordable and display quite 
good results in terms of large-scale population diagnosis. However, they all present certain 
minor concerns with regards to their reproducibility, reliability, specificity (those using 
whole parasites) and sensitivity (those using parasite fractions and/or recombinant antigens) 
which, in turn affect their overall performance. In addition, and likely due to their biased 
antigenic composition, they also show suboptimal performance with particular Chagasic 
populations (i.e. acute and/or congenital infections) (Gomes, Lorena and Luquetti, 2009), 
and often discordant results between assays depending on the geographic origin of the 
patients (Caballero et al., 2007; Guzman-Gomez et al., 2015). The latter may be attributed to 
variations in the local human immune responses and/or, as stated above, to differences in the 
antigenic constitution of T. cruzi DTUs that prevail in different endemic areas. Importantly, 
even after successive improvements, none of the available tests emerged as the ‘gold 
standard’, i.e. able to show ~100% specificity and sensitivity. In this context, current 
guidelines developed by the World Health Organization advice the use of at least two 
serological tests based on different principles for reaching a 'conclusive' diagnosis. In the 
case of ambiguous or discordant results, a third technique should be conducted. These 
guidelines thereby increase the cost of diagnosis and risk of patient ‘loss’, particularly in 
endemic areas. Most importantly, these diagnostic limitations delay the initiation of 
chemotherapy, thus limiting its efficacy.
MOLECULAR METHODS
In the late 1980's, DNA-based molecular methods emerged as an appealing alternative for 
the diagnosis of Chagas disease, mainly to overcome the low sensitivity of direct 
parasitological approaches (Moser, Kirchhoff and Donelson, 1989; Sturm et al., 1989). The 
introduction of the recently developed polymerase chain reaction (PCR) assay, in particular, 
held promises of high sensitivity, specificity, and high-throughput potential. The first targets 
for PCR amplification were focused on the major molecular component of the mitochondrial 
DNA (also known as kinetoplast DNA or kDNA). In T. cruzi and other kinetoplastid 
parasites, this component is present in the form of circular DNA of short length (mini-
circles), which add up to several thousand copies per cell (Simpson, 1986). Later on, a large 
repertoire of kDNA or nuclear DNA targets including single- or multi-copy genes and 
satellite sequences, as well as different multi-target strategies have been explored (Schijman 
et al., 2011). More recently, a parasite concentration approach based on short and stable 
RNA aptamers was developed to facilitate PCR-based detection methods, and proposed as a 
potential alternative tool in monitoring parasite load in Chagasic patients (Nagarkatti et al., 
2012; Nagarkatti et al., 2014).
Major challenges for the clinical implementation of PCR-based techniques derive from a 
number of technical factors such as source (i.e. cord blood, umbilical tissue, placental, 
tissue), volume, conservation and transportation of the samples, and underlying molecular 
biology protocols (i.e. DNA isolation, purification, pre-treatment, thermo-cycling 
conditions, etc.) (Schijman et al., 2011). In addition, the reproducibility and overall 
performance of PCR-based methods is significantly affected by the fluctuations in 
parasitemia that characterize the chronic phase of Chagas disease, and by inter-DTU 
variations in dosage and/or sequence of the targets of amplification (Lewis et al., 2009b). 
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Despite these issues, several PCR- and, more recently, quantitative real-time PCR (qPCR)-
based procedures have been developed. These allowed detection and quantification of 
parasite DNA from clinical samples with variable levels of reliability, complexity, selectivity 
and analytical sensitivity (Duffy et al., 2009; Duffy et al., 2013; Piron et al., 2007; 
Qvarnstrom et al., 2012; Valadares et al., 2008). In a recent work, a multicentre trial 
optimized and evaluated in parallel two last generation qPCR methods targeting either 
satellite or kDNA targets (Ramirez et al., 2015). These methods were tested using a large 
and heterogeneous panel of blood samples from acute and chronic patients either 
asymptomatic or showing different clinical manifestations, and infected through different 
transmission modes (Ramirez et al., 2015). Though highly specific and reproducible, both 
methods showed clinical sensitivities of ~80%, which is still not good enough for their 
application as confirmatory testing of blood donors or in clinical settings. In addition, it is 
worth noting that DNA-based molecular methods are expensive and difficult to be 
implemented in endemic areas, e.g. in PoC sites with limited infrastructure (Table 1).
DIAGNOSTIC APPLICATIONS FOR CHAGAS D ISEASE: PENDING ISSUES
As described above, current diagnostic methods and particularly those based on serology are 
highly accurate in detecting most of T. cruzi infections in humans. However, there are some 
clinical and/or epidemiological situations, discussed in this section, in which their 
performance is significantly hampered by methodological and/or biological issues.
EARLY DIAGNOSIS OF CONGENITAL TRANSMISSION
According to epidemiological data, maternal-fetal transmission occurs in an average of 5% 
of infected mothers in endemic areas, thus leading to ~15,000 congenital cases per year 
(Carlier and Truyens, 2015). Diagnosis in newborns is commonly based on the microscopic 
observation of trypomastigotes in peripheral and/or umbilical cord blood, which is more 
effective by the microhematocrit concentration technique (Freilij and Altcheh, 1995). 
Considering the usually high parasitemia at the initial stage, PCR-based analyses provide a 
valuable supporting tool to detect infection and to evaluate treatment outcome in these 
patients (Table 1) (Duffy et al., 2009; Russomando et al., 1998; Schijman et al., 2003). 
Standard serodiagnostic methods, though routinely used have low positive predictive value 
until 8–9 months after birth due to passive transfer of maternal IgG antibodies (Freilij and 
Altcheh, 1995). In this context, identification of novel antigens recognized by fetal IgM or 
IgA appeared as an appealing approach. However, and despite initial promising results 
(Antas et al., 2000; Betonico et al., 1999; Corral, Altcheh and Freilij, 1998; Lorca et al., 
1995), these efforts have been discontinued due to the high number of false-negatives 
(Blanco et al., 2000; Freilij and Altcheh, 1995; Gomes, Lorena and Luquetti, 2009). It 
should be noted though, that a serious, high-content and unbiased screening for congenital 
IgM specificities have not been yet undertaken.
As an alternative approach to discover surrogate markers of congenital infection, the group 
of Dr. Frasch in Argentina undertook the identification of T. cruzi antigens exclusively 
and/or preferentially recognized by fetal IgGs. This approach relied on the parallel 
evaluation of paired mother/newborn serum samples against a multiplexed antigen panel 
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followed by the comparison between signatures of recognition. Using this strategy, they 
identified SAPA (Shed Acute-Phase Antigen) and, to a lesser extent, Ag13/TcD as suitable 
markers to detect congenital transmission (Table 1) (Reyes et al., 1990). Both antigens 
belonged to the above mentioned T. cruzi 'parental repertoire' and, interestingly, both 
(particularly SAPA) had been previously found to display a biased, though not exclusive 
recognition towards acute infection sera (Affranchino et al., 1989). This is consistent with 
the assumption that congenital T. cruzi infection constitutes in fact an acute infection in 
newborns (Carlier and Truyens, 2015).
Further research disclosed that SAPA is a repetitive sequence displaying a complex antigenic 
structure (Alvarez et al., 2001) and involved in improving the pharmacokinetics of trans-
sialidase, a major T. cruzi virulence factor (Buscaglia et al., 1999; Dc-Rubin and 
Schenkman, 2012; Frasch, 2000). Up to this day, SAPA remains the only available 
serological marker of early infection and has been widely used to diagnose recently-acquired 
vector-borne infections and congenitally transmitted cases (Mallimaci et al., 2010; 
Russomando et al., 2010; Volta et al., 2015).
More sophisticated, laborious and difficult to interpret methods were also developed. These 
include testing of the newborn sample by immunoblot against the TESA fraction (Table 1) 
(Umezawa et al., 1996) and, more recently, the Chunap (Chagas urine nanoparticle) test 
(Castro-Sesquen et al., 2014). In the latter method, instead of T. cruzi-specific antibodies, 
active infection is indirectly assessed by the capture and concentration of T. cruzi TESA 
antigens from patient's urine, which are then revealed using a monoclonal antibody directed 
to a parasite lipophosphopeptideglycan, included in the test (Castro-Sesquen et al., 2014). 
When evaluated on children living in endemic areas and tested at the peak of parasitemia 
(~1-month old) Chunap was able to accurately diagnose congenital infections (Castro-
Sesquen et al., 2014), and is now being evaluated for other diagnostic applications (Castro-
Sesquen et al., 2016).
On a final note, it should be stressed that given the high efficacy of trypanocidal drugs in 
infected newborns, their rapid diagnosis and subsequent treatment is essential. Intensive 
screening for distinctive immune responses (i.e. those based on IgM and/or IgA antibodies) 
and/or for specific molecular signatures that may translate into surrogate biomarkers for 
early detection of congenital T. cruzi transmission should be thus considered a top-ranking 
priority in Chagas disease applied research.
RAPID ASSESSMENT OF THERAPY EFFICACY
Overall, the best chemotherapy results have been achieved in acute or early chronic 
infections. However, even in children the cure rate is up to 62% at 2 years of follow-up, 
although this figure may vary according to population and geographical location (Ribeiro et 
al., 2009). This variability may be attributed in part to differences in the prevalence of 
human-associated genotypes across endemic areas. Indeed, substantial inter-strain variations 
in drug resistance have been ascertained both in in vitro systems and in animal infection 
models (Figure 1) (Moraes et al., 2014; Toledo et al., 2003).
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During the chronic stage, the efficacy of drug treatment is lower and variable; and is also 
difficult to assess because most studies used different treatment regimens and outcome 
evaluation methods (variable assays, frequency and duration of follow-up) (for a recent 
review, see (Pinazo et al., 2014)). Even in successful treatments, the gold standard for 
evaluating drug efficacy, which relies on consistent negative results using conventional 
parasitological and whole parasite-based serological tests, may take years to decades to 
assess, thus stressing the necessity of novel and improved therapeutic response markers.
Several therapeutic studies support the usefulness of PCR-based strategies to evaluate 
treatment outcome in congenital or acute cases of Chagas disease. Moreover, PCR-based 
methods may also assist, though with sub-optimal performance in cases of lower 
parasitemias, in evaluating chemotherapy in chronic cases of Chagas disease (Britto et al., 
1995; Galvao et al., 2003; Munoz et al., 2013; Russomando et al., 1998; Schijman et al., 
2003). In particular, PCR-based methods seem to be a rapid indicator of the parasite’s 
susceptibility to drugs, allowing early therapy modification in cases of resistance or 
reactivation of Chagasic infection (Lages-Silva et al., 2002; Pinazo et al., 2014; Schijman et 
al., 2000).
In 1982, Drs. Krettli and Brener in Brazil demonstrated the existence of a special type of 
antibodies, which they termed 'antibodies against living blood forms', that were absent in 
parasitological cured hosts early after drug treatment (Krettli and Brener, 1982). These 
antibodies were shown to participate in resistance against T. cruzi and were solely detectable 
by complement-mediated lysis (CoML) assays (Krettli and Brener, 1982). Upon these 
findings, the authors proposed the inclusion of the CoML technique in the context of cure 
criteria. Indeed, the CoML technique offered an important contribution for post-therapeutic 
monitoring of Chagas disease in clinical trials, mostly by significantly reducing the required 
follow-up periods (Table 1) (Galvao et al., 1993). Numerous improvements in terms of the 
sensitivity and operational safety of the CoML method have been later on introduced 
(Alessio et al., 2014; Martins-Filho et al., 2002; Vitelli-Avelar et al., 2007). Most 
importantly, this concept of 'non-conventional' serological responses set the basis for 
multiple screenings looking for parasite molecules that could be the target of antibody 
responses showing different qualitative, quantitative and/or kinetic properties. Several 
potential biomarkers have been thereby identified and evaluated for their post-therapeutic 
application (Andrade et al., 2004; Fernandez-Villegas et al., 2011; Gazzinelli et al., 1993; 
Laucella et al., 2009; Machado-de-Assis et al., 2012; Sanchez Negrette et al., 2008; Silva et 
al., 2002). They included different parasite fractions (i.e. TESA, F2/3), individual 
recombinant antigens belonging to the 'parental repertoire' such as F29/FCaBP/Tc-24/
Tc-28/1F8 (Sosa Estani et al., 1998), and other molecules such as TSSA (our unpublished 
results) (Table 1). Overall, the best results were obtained with the F2/3 fraction (Table 1) 
(Andrade et al., 2004; de Andrade et al., 1996). Interestingly, antibodies directed to α-
galactosyl-containing epitopes (i.e. the main antigenic determinant in the F2/3 fraction), 
were later on shown to induce trypomastigote lysis independently of complement (Pereira-
Chioccola et al., 2000).
More recently, the group of Dr. Tarleton explored the use of a multi-pronged approach based 
on the simultaneous evaluation of T. cruzi-specific B- and T-cell responses as an alternative 
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way of measuring treatment efficacy (Alvarez et al., 2016; Laucella et al., 2009). By doing 
so, both a decline in the frequency of IFNγ-producing T cells and in antibody titers 
measured by a previously developed recombinant multiplex serological assay (Cooley et al., 
2008) were observed shortly after benznidazole treatment and were thus proposed as 
surrogate markers for refining the post-therapeutic cure criterion (Albareda and Laucella, 
2015; Alvarez et al., 2016; Laucella et al., 2009). Identification of novel biomarkers for early 
evaluation of anti-trypanocidal drug efficacy will fasten and improve the assessment of 
current chemotherapy treatments in clinical trials and, importantly, will be instrumental for 
the development of novel and improved treatments.
INDICATION/PREDICTION OF CHAGAS DISEASE PROGRESSION
As mentioned, Chagas disease evolves into a wide range of pathological symptoms, ranging 
from subclinical to potentially fatal megasyndromes (Rassi, Rassi and Marin-Neto, 2010). 
Identification of diagnostic and/or predictive biomarkers of disease progression would 
therefore represent a major achievement towards improving the clinical management of 
Chagasic patients. Some authors proposed serological alternatives to tackle this issue, such 
as quantifying the antibody titers to Ag1/JL7/FRA/H49 to distinguish between Chagas 
disease-associated cardiac pathology and other non-Chagasic cardiological dysfunctions 
(Table 1) (Abraham and Derk, 2015; Bhattacharyya et al., 2014; Kaplan et al., 1997; Levin 
and Hoebeke, 2008; Thomas et al., 2012). On the other hand, antibodies to another 'parental 
repertoire' antigen, termed JL5, were shown to cross-recognize endogenous β1-adrenergic 
and M2 muscarinic receptors. Such 'auto-antibodies' were shown to be associated with 
arrhythmogenic anomalies, which may contribute to cardiac alterations in Chagasic patients 
(Kaplan et al., 1997), and were thus proposed to be included in the context of disease 
prognosis (Table 1). More recently, a certain correlation between serological responses to 
TSSA and electrocardiogram abnormalities was also noted (Table 1) (Bhattacharyya et al., 
2014).
Alternatively, several groups attempted to identify biochemical markers of cardiac damage 
and/or inflammation such as TNF-α (Talvani et al., 2004a), angiotensin-converting enzyme 
2 (ACE2) (Wang et al., 2010), Brain and Atrial Natriuretic Peptides (BNP and ANP, 
respectively) (Garcia-Alvarez et al., 2010; Heringer-Walther et al., 2005; Ribeiro et al., 
2002) as candidates for disease prognosis (Table 1). In particular, the concentration of BNP 
and ANP in serum were systematically studied as markers of heart damage in Chagasic 
patients (Garcia-Alvarez et al., 2010; Heringer-Walther et al., 2005; Ribeiro et al., 2002) 
since they had been previously related with cardiovascular diseases (Wang et al., 2006; 
Wondergem et al., 2001). Increased concentrations of BNP and ANP strongly correlated 
with the severity of Chagas-associated cardiac damage, being BNP more sensitive than ANP 
(Fernandes et al., 2007; Heringer-Walther et al., 2005; Talvani et al., 2004b). Upon these 
findings, the authors proposed that BNP could be measured periodically in asymptomatic 
patients as screening test to detect incipient ventricular dysfunction (Heringer-Walther et al., 
2005). In the same line, higher levels of plasma ACE2, that catalyzes the conversion from 
angiotensin II to angiotensin 1–7 (Keidar, Kaplan and Gamliel-Lazarovich, 2007), were 
shown to correlate with clinical severity and worsening echocardiographic parameters in 
Chagasis patients (Wang et al., 2010). More importantly, given that the combined 
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determination of BNP concentration and ACE2 activity had better positive predicted value 
than when separately analyzed, authors encouraged the use both markers to predict fatal 
outcomes (Wang et al., 2010).
In the same line, the role of endothelin-1 (ET-1) as a prognostic marker for T. cruzi-induced 
pathogenesis has also been extensively studied, though in animal models. ET-1 is a 
vasoactive peptide synthesized by many cell types including cardiac myocytes and cardiac 
fibroblasts associated with vasospasm, vascular damage, cardiovascular remodeling and 
inflammation (Kedzierski and Yanagisawa, 2001). Mice infected with T. cruzi exhibit 
increased levels of ET-1 and endothelin converting enzyme (ECE), the enzyme responsible 
for the conversion of the precursor to ET-1, in plasma, in the vasculature and in T. cruzi-
infected myocardial cells (Huang et al., 2000; Petkova et al., 2000). Interestingly, 
phosphoramidon, an inhibitor of ECE, ameliorated the pathology and reduced the extent of 
cardiac remodeling in these animals (Jelicks et al., 2002). Moreover, ET-1 KO mice showed 
certain protection against chronic Chagasic cardiomyopathy (Tanowitz et al., 2005).
Overall, and despite multiple and disparate attempts, none of the serological and/or 
biochemical markers that have been explored so far translated into a reliable, easy to assay 
and interpret marker to asses cardiac damage and/or disease prognosis (recently reviewed in 
(Pinazo et al., 2015)). The complex and likely multifactorial nature of Chagas disease 
pathogenesis together with intrinsic difficulties in establishing appropriate experimental/
epidemiological models converge in turning this area as the most challenging in terms of T. 
cruzi biomarker discovery.
TYPING OF INFECTING PARASITE STRAIN(S)
Pioneer studies aimed at fingerprinting the infecting parasite strain(s) directly in clinical 
samples were based on biochemical markers (i.e. MLEE, Multi-Locus Enzyme 
Electrophoresis) (Tibayrenc and Ayala, 2015). Recent advances in typing schemes based on 
RFLP (Restriction Fragment Length Polymorphism), PCR-RFLP, RAPD (Random 
Amplification of Polymorphic DNA), DNA hybridization, karyotyping and, particularly, 
sequence-based markers either using a single locus or multiple loci have greatly improved 
parasite genotypic resolution in vitro (Table 1) (Tibayrenc and Ayala, 2015). However, in 
vivo, these genotyping methods are time-consuming and costly, and require parasite 
isolation and amplification or a high quantity of DNA, therefore necessitating invasive 
sampling with medical risks. Moreover, the fact that concurrent infections with multiple T. 
cruzi strains appears to be the norm rather than the anomaly (Perez, Lymbery and 
Thompson, 2014), and the discovery that the most prevalent T. cruzi genotype present in the 
bloodstream can differ from the strain(s) found sequestered within organs (Manoel-Caetano 
Fda et al., 2008; Vago et al., 2000) further complicate this task. In this context, serotyping 
methods emerge as an appealing alternative to overcome these limitations, as demonstrated 
in other human infectious diseases (Dunbar et al., 2015; Maksimov et al., 2012). Serotyping 
is based on the use of specific antigens with qualitative and/or quantitative differences 
among parasite strains/DTUs to detect strain-specific antibody signatures.
TSSA (Di Noia et al., 2002) is a parasite adhesin displaying significant sequence homology 
to TcMUC, a huge family of polymorphic genes that code for the polypeptide backbones of 
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the trypomastigote mucin molecules (Buscaglia et al., 2004; Campo et al., 2006), some of 
which are terminally decorated with α-galactosyl residues and constitute the F2/3 antigenic 
fraction. Interestingly, detailed genetic characterization of the TSSA locus disclosed minor 
sequence variations between TSSA variants expressed by different parasite DTUs 
(Bhattacharyya et al., 2010; Di Noia et al., 2002). Some of these variations were shown to 
have major impact on TSSA biological function and antigenicity, thereby leading to 
differential antibody profiles between variants (Balouz et al., 2015; Bhattacharyya et al., 
2014; Canepa et al., 2012; De Marchi et al., 2011; Di Noia et al., 2002). So far, TSSA 
remains the only polymorphic antigen that has been successfully used for the development 
of DTU-specific serology methods for T. cruzi infections of humans (Table 1) 
(Bhattacharyya et al., 2014; Bisio et al., 2011; Burgos et al., 2010; Longhi et al., 2014; Risso 
et al., 2011). Despite this, the resolution and specificity of TSSA-based serotyping assays 
need to be improved. Discrimination between certain DTUs remains challenging as they 
possess identical or almost identical TSSA alleles or they are poorly immunogenic 
(Bhattacharyya et al., 2014; Canepa et al., 2012).
Serotyping could be a rapid, sensitive, cost-effective and relatively non-invasive alternative 
to stringent T. cruzi genotyping in humans, and may also be used in animal reservoirs for 
epidemiological studies (Bhattacharyya et al., 2015; Cimino et al., 2011). Most importantly, 
development of novel serotyping tools will facilitate the unraveling of possible relationships 
between parasite genetic variability and clinical features, a major issue in Chagas disease 
applied research.
POINT-OF-CARE DIAGNOSIS
People living in Chagas disease endemic areas have restricted access to laboratory facilities 
and/or to appropriate health centers. This, together with the associated costs and expertise 
needed for conventional diagnostic methods point to a number of technological and 
economic barriers that further stress the need to deploy PoC tests for T. cruzi infection 
diagnosis. PoC devices, in addition, allow the patients to see the results for themselves, 
which contributes to a better working relationship between local communities and people 
carrying out the testing (e.g., during field surveys). Moreover, the need for follow-up visits 
to surveyed individuals and therefore the operational costs and risks of possible attrition bias 
are reduced. From an epidemiological point of view, a reliable PoC test would allow 
intervention strategies to be implemented in situ, such as for serologic surveillance, vaccine 
or clinical trials; as well as for rapid initiation of treatment of infected individuals during 
outbreaks of acute cases, such as those recently reported (Alarcon de Noya et al., 2010; 
Segovia et al., 2013).
Several rapid diagnostic and PoC tests to detect infection based on immunochromatography, 
particle agglutination, immunofiltration, immunodot, lateral-flow immunochromatographic 
assays (LFIA) or DNA detection are available for a variety of infectious diseases (Nair et al., 
2016; Natoli et al., 2014; Teles and Fonseca, 2015). These may be either qualitative or semi-
quantitative and are characterized by the delivery of quick results, in most cases without the 
need for electrical equipment. In the case of Chagas disease, several LFIAs based on 
antigenic fractions or recombinant antigens and a single PoC test aimed at the capture and 
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concentration of T. cruzi TESA antigens in urine samples (Chunap, see above) were 
developed (Table 1) (Castro-Sesquen et al., 2014; Houghton et al., 2009; Reithinger et al., 
2010). Serological tests, however show substantial variations in their sensitivity in different 
geographical areas (Verani et al., 2009), and display sub-optimal performances (Sanchez-
Camargo et al., 2014). Unfortunately, and despite being widely used in different parasitic 
diseases (Mondal et al., 2016; Sriworarat et al., 2015), PCR-based methods applicable in 
PoC settings such as those based on simple colorimetric loop-mediated isothermal 
amplification or Recombinase Polymerase Amplification (RPA) techniques are not yet 
available for T. cruzi detection.
As a first step towards the development of alternative PoC devices for diagnosis, a new 
diagnostic platform based on superparamagnetic microbeads coated with recombinant 
antigens and fluorescent (FMBIA) or electrochemical (EMBIA) detection was recently 
developed (Cortina et al., 2016). The EMBIA platform, including antigen-functionalized 
magnetic microbeads, disposable electrochemical cells-electrode cartridges and a portable 
potentiostat, was evaluated for serodiagnosis of human and cattle infectious diseases. In the 
particular case of Chagas disease, a more extensive validation was performed showing that 
the EMBIA platform displayed an excellent diagnostic performance almost indistinguishable 
from the well-established ELISA methods (Cortina et al., 2016).
DIAGNOSTIC APPLICATIONS FOR CHAGAS D ISEASE: THE ROAD AHEAD
As discussed throughout this chapter, parasite-specific immune signatures provided a prime 
source of biomarker candidates for development of Chagas disease diagnostic applications 
(see Table 1). However, they may now be re-explored using modern and powerful ‘omics’-
based fingerprint approaches. Indeed, the availability of complete T. cruzi genomes from 
several strains together with a variety of recent genome mining exercises were performed to 
identify potential serodiagnostic reagents and vaccine candidates (Bhatia et al., 2004; 
Carmona et al., 2012; Cooley et al., 2008; Goto, Carter and Reed, 2008; Reis-Cunha et al., 
2014). Importantly, most of the antigens that emerged from these in silico-guided screenings 
were not included in the ‘parental repertoire' (Table 1), and could thereby entail novel 
diagnostic capabilities, such as early assessment of drug efficacy (Alvarez et al., 2016; 
Laucella et al., 2009). Genome-wide approaches could be also used as a starting point to 
identify novel DNA-based DTU-resolution markers (Cosentino and Aguero, 2012) and/or 
novel serotyping reagents. As previously shown, genetic variation among T. cruzi DTUs 
translates into differential proteomes (Telleria et al., 2010) and, therefore also likely in 
distinct epitope collections ('epitomes') recognized during human infections. By carrying out 
genome-wide B-cell epitope prediction on proteins derived from allelic pairs of the hybrid T. 
cruzi CL Brener genome, the group of Dr. Bartholomeu in Brazil was able to identify three 
novel polymorphic epitopes potentially able to discriminate between parasite DTUs (Mendes 
et al., 2013). Unfortunately, this study and those mentioned above were somehow limited by 
the use of low-to-medium throughput antigen expression/synthesis approaches, and/or by the 
use of non-human sources of serum samples.
Recent advances in computerized photolithography and photochemistry, however have 
allowed the development of a novel peptide-chip technology where up to 1 million 
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individual peptides are synthesized in situ on a glass slide (Buus et al., 2012). This in situ 
synthesis makes the production of the chip highly cost-effective and allows, for the first 
time, to interrogate complete proteomes. Recent work in our laboratories demonstrated both 
the high technical reproducibility as well as epitope mapping consistency of this platform 
when compared with earlier technologies (Balouz et al., 2015; Carmona et al., 2015). Most 
importantly, by screening the complete length of 457 parasite proteins (~7% of the T. cruzi 
deduced proteome) we were able to identify 2,031 Chagas disease-specific peptides and 97 
novel parasite antigens (Carmona et al., 2015). Together with above mentioned studies, and 
besides emphasizing the huge potential of genomic/proteomic methods as major driving 
forces in antigen discovery, these findings indicate that a vast majority of the T. cruzi 
antigenic repertoire remains uncharacterized. We aim now at interrogating the entire T. cruzi 
deduced proteome, including inter-strain polymorphisms revealed by previously developed 
genetic diversity maps (Ackermann et al., 2012; Panunzi and Aguero, 2014). The use of 
samples collected from particular patients populations such as infected with different 
parasite DTUs or showing distinct Chagas disease-associated pathologies followed by a final 
integration of the emerging data will put us in position to discriminate between the common 
linear B-cell 'epitome' of T. cruzi and sets of epitopes showing differential recognition 
among distinct Chagas disease populations.
Considering the huge functional and diagnostic significance of carbohydrates on T. cruzi 
biology (de Lederkremer and Agusti, 2009), it could be hypothesized that similar high-
throughput approaches carried out on glycan and/or lectin microarrays (Fernandez-Tejada, 
Canada and Jimenez-Barbero, 2015) will have a major impact on Chagas disease biomarker 
discovery. These methodologies have been successfully explored in different parasitic 
infections (Anish et al., 2013; Aranzamendi et al., 2011; Martin et al., 2013).
From a wider perspective, high-throughput strategies may be also pursued to develop novel 
biomarkers based on the detection of T. cruzi-derived molecules (Castro-Sesquen et al., 
2014; de Titto and Araujo, 1988) and/or parasite-induced modifications o n host molecules 
and/or cells (Li et al., 2016; Mucci et al., 2002; Muia et al., 2010; Risso et al., 2007; Trocoli 
Torrecilhas et al., 2009). Theoretically, these strategies would have the additional advantage 
to discriminate between active from past infections and/or to assist in monitoring disease 
progression, as validated in other human diseases (Karsdal et al., 2010; Leeansyah et al., 
2013; Tritten et al., 2014). In this context, it is important to keep in mind i) the extent of 
variability due to host genetic background on setting these putative biochemical markers and 
ii) that T. cruzi-derived molecules, and particularly during the chronic phase of Chagas 
disease, are present in biological fluids at extremely low concentrations, and likely 
aggregated in membrane-coated vesicles (Bayer-Santos et al., 2013; Fernandez-Calero et al., 
2015; Lantos et al., 2016; Trocoli Torrecilhas et al., 2009).
Nevertheless, modern ‘-omic’ technologies are offering alternative strategies for such a 
difficult system biology exploration (Cantacessi et al., 2015; Hockl et al., 2016; Preidis and 
Hotez, 2015). In particular, mass spectrometry (MS) methods provide a robust, versatile and 
sensitive analytical technology allowing high-throughput detection with mass accuracy, 
precise quantitation and verification of protein variants, splice isoforms, metabolites and 
disease-specific post-translational modifications (Crutchfield et al., 2016). Indeed, using 
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MS-based approaches, global changes in metabolic profiles in Chagasic patients showing 
acute myocarditis (Girones et al., 2014) and serological biomarkers showing differences 
between Chagasic and healthy subjects (Santamaria et al., 2014) were recently identified. In 
the latter case, biomarker peaks with the best discriminatory power were further 
characterized by a range of proteomic and immunological techniques, indicating that 
specific fragments derived from proteolysis of apolipoprotein A-I and one fragment of 
fibronectin are specifically upregulated in Chagasic patients (Santamaria et al., 2014). 
Interestingly, these biomarkers returned to normal values more rapidly than whole parasite-
based serological tests in patients treated with nifurtimox, thus supporting their potential use 
for evaluation of therapeutic efficacy (Table 1) (Santamaria et al., 2014).
In addition to the obvious impact in the diagnostic application field, it is expected that the 
utilization of these and other high-throughput, '-omic' techniques will provide a vast amount 
of putative biomarkers to be explored in other Chagas disease research areas such as 
molecular epidemiology and prioritization of targets for vaccine development. Most 
importantly, together with appropriate animal models and robust bioinformatics, molecular 
and cellular tools (Aguero et al., 2008; Crowther et al., 2010; Katsuno et al., 2015; Lewis et 
al., 2015; Magarinos et al., 2012; Moraes et al., 2014), these biomarkers will be instrumental 
to screen, prioritize and evaluate safety and efficacy of novel drugs/treatments.
CONCLUDING REMARKS
Over 100 years after its discovery, and despite its huge medical, economic and social burden, 
Chagas disease remains a major threat in several countries of Latin America and an 
emergent global health problem. Great efforts have been made and are still being made in 
Latin America and other developed countries to halt T. cruzi transmission. However, one of 
the key issues concerning Chagas disease control remains that of diagnosis. Without 
accessible and effective diagnostics tools and methods, infected individuals cannot be timely 
identified and hence treated. Even if treated, the success of treatment cannot be efficiently 
assessed.
As discussed here, current diagnostic methods are highly accurate in detecting most of T. 
cruzi infections in humans. However, there are still some clinical and/or epidemiological 
situations in which their performance is severely impaired. In addition, the complex 
epidemiological features of Chagas disease and the remarkable phenotypic diversity 
displayed by distinct T. cruzi strains, which may be associated to certain aspects of disease 
progression/outcome, also stress the necessity of developing new methods able to be 
deployed in PoC settings and capable of typing the infecting parasite(s) directly in clinical 
samples. The implementation of modern ‘-omic’, high-throughput and aggressive strategies 
constitutes an appealing alternative to move on towards filling current diagnostic gaps. 
Emergent diagnostic tests integrating these novel and tailored tools will provide a significant 
impact on the effectiveness of current intervention schemes and, most importantly, will 
improve the clinical management of Chagasic patients by providing the intervening 
physician with an accurate and integrated diagnosis.
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FIGURE 1. 
Schematic diagram showing the T. cruzi life cycle and different biological features that 
contribute to ensure its transmission and the establishment of multiple interactions with 
insect vectors and infected humans. Those features for which there is direct or indirect 
experimental evidence suggesting inter-strain variability are denoted in italics.
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Table 1
Overview of performance and features of available diagnostic applications for Chagas disease.
1
Performance is arbitrarily indicated as appropriate (green boxes), non-appropriate (vermillion boxes) or intermediate/needs to be improved 
(yellow boxes) according to available data. N.A. and question marks (?) stand for non-applicable or not enough experimental data available to 
assess the performance, respectively.
2Adaptability to be deployed in PoC settings, which depends on specific features of the tool/technique and which is arbitrarily indicated as above.
3Commercially available from different vendors.
4
TESA assays include diverse techniques that measure anti-TESA antibodies in serum samples (i.e. TESA-ELISA, TESA-dot blot, TESA-blot) and 
techniques that capture TESA antigens directly in urine samples (i.e. Chunap assays)
5
The term 'parental' repertoire refers to T. cruzi antigens identified in large-scale initiatives carried out in the 80's, and includes: Ag1/JL7/FRA/
H49; Ag2/B13/TCR39/PEP-2; Ag10; Ag13/TcD; Ag19; Ag26; Ag30/CRA/JL8/TCR27; Ag36/JL9/MAP; Ag54; JL1; JL5; JL9; SAPA; B12; TcE; 
A13; F29/FCaBP/Tc-24/Tc-28/1F8; Tc-40; HSP70; HSP78 and FL-160, according to current nomenclature. These antigens were assayed for 
conventional diagnosis in different combinations using a variety of technological platforms (ELISA, LFIA, Western blot, dot blot), some of which 
are commercially available from different vendors. The individual performance of some of these antigens showing particular features is indicated 
below.
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6
Include RFLP, PCR-RFLP, RAPD, Southern blot and other DNA hybridization methods, karyotyping methods and sequence-based methods either 
using a single locus or MLST.
7
Include TNF-α, ACE2, BNP, ANP, ET-1 and other biochemical markers indicated in text.
All of abbreviations are defined in the text. Briefly: PoC, Point-of-Care; HIA, Hemagglutination Inhibition Assay; IFA, Immunofluorescence 
Assay; ELISA, Enzyme Linked Immunosorbent Assay; F2/3: Purified highly O-glycosylated and antigenic trypomastigote mucins; CoML, 
Complement-Mediated Lysis; TESA, Trypomastigote Excreted-Secreted Antigens; LFIA, Lateral-Flow Immunochromatographic Assays; SAPA, 
Shed Acute-Phase Antigen; TSSA, Trypomastigote Small Surface Antigen; PCR, Polymerase Chain Reaction; PCR-RFLP, PCR-based Restriction 
Fragment Length Polymorphism assay; MLST, Multi-Locus Sequence Typing assay; RAPD, Random Amplification of Polymorphic DNA; TNF-α, 
Tumor Necrosis Factor α; ACE2, Angiotensin-Converting Enzyme 2; BNP, Brain Natriuretic Peptide; ANP, Atrial Natriuretic Peptide; ET-1, 
Endothelin-1.
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